Previous 10 | Next 10 |
NOVATO, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Brazil’s National Health Surveillance Agenc...
NOVATO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D....
Image source: The Motley Fool. Ultragenyx Pharmaceutical inc (NASDAQ: RARE) Q2 2021 Earnings Call Aug 2, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Ultragenyx Pharmaceutical inc (RARE) Q2 2021 Earnings Call Tra...
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2021 Earnings Conference Call July 30, 2021, 05:00 PM ET Company Participants Joshua Higa - Director, IR Emil Kakkis - President and CEO Erik Harris - Chief Commercial Officer Camille Bedrosian - Chief Medical Officer Conference Call Participants Maury...
Second quarter 2021 total revenue of $87.0 million including Crysvita 1 revenue to Ultragenyx of $44.7 million 2021 Crysvita revenue in Ultragenyx territories 1 guidance of $180 million to $190 million reaffirmed Strong Dojolvi launch continues with...
My actively managed Roth IRA portfolio of 30 CEFs and 28 REITs for income, and 135 stocks for swing trading mostly under-performing S&P 500 stocks, continue to realize profits. In July, I closed 6 stock trades for a net gain, including dividends, of 32.14% (median) or 30.61% (cost...
NOVATO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Monday, August ...
libre de droit/iStock via Getty Images Ultragenyx Pharmaceutical (RARE) announces that the U.S. FDA and the European Commission ((EC)) have granted Orphan Drug Designation for UX053 for the treatment of Glycogen Storage Disease Type III ((GSDIII)). GSDIII is a disease caused by a glycoge...
NOVATO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Admin...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperformed in a second-quarter rotation in...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...